TerminatedPhase 2

The Impact of Oxidative Stress on Erythrocyte Biology

Stopped: Funding not renewed

United States8 participantsStarted 2022-01-02

Plain-language summary

This study will address if red blood cells transfused to a sickle cell patient from a donor with a glucose-6-phosphate-dehydrogenase (G6PD) enzyme deficiency have a different lifespan as measured by the percentage of red blood cells that survive post-transfusion compared to red blood cells transfused to a sickle cell patient from a donor without a G6PD enzyme deficiency.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-60 years * Has diagnosis of sickle cell disease * Steady state (no pain or baseline pain and ≥1 month from any hospital admission) * Receiving chronic transfusions (i.e., regular transfusion every 4-8 weeks). Exclusion Criteria: * History of transfusion reactions not adequately managed by antihistamines * Does not have crossmatch compatible red cells * Known G6PD deficiency * Hepato- or splenomegaly * Participation in another therapeutic trial * Pregnant or nursing * HIV positive * At investigator discretion for uncontrolled inter-current illness or social situation limiting compliance with study requirements. * Inability to speak and/or read English

What they're measuring

Percentage of Red Blood Cells Surviving

Timeframe: 24 hours post-transfusion

Trial details

NCT IDNCT04028700

SponsorUniversity of North Carolina, Chapel Hill

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-18

Results submitted2025-05-15

View on ClinicalTrials.gov More Sickle Cell Disease Without Crisis trials